Serum Magnesium and Mortality in Hemodialysis Patients in the United States: A Cohort Study.

Background Low serum magnesium levels in patients with kidney disease have been linked to increased mortality. This study investigated whether similar associations existed in maintenance hemodialysis (HD) patients. Study Design Cohort study. Setting & Participants All Fresenius Medical Care North America in-center HD patients with available serum magnesium measurements were studied. The initial exploratory study in 21,534 HD patients evaluated associations among serum magnesium level, dialysate magnesium concentration, and mortality from April 2007 through June 2008. The follow-up study in 27,544 HD patients evaluated associations between serum magnesium levels and mortality over 1 year (January through December 2008). Predictors The primary predictor was serum magnesium level, with adjustment for case-mix (age, sex, race, diabetes, and dialysis vintage and additionally for follow-up study: body surface area and vascular access) and laboratory variables (albumin, hemoglobin, phosphorus, equilibrated Kt/V, potassium, calcium, and intact parathyroid hormone values). Outcome Primary outcome variable was 1-year mortality risk, evaluated using Cox proportional hazards models. Results Among 21,534 HD patients in the exploratory study, there were 3,682 deaths. Higher dialysate magnesium level was associated with higher serum magnesium level ( R =0.22; P Limitations Observational study with cross-sectional serum magnesium measurements and no information for oral magnesium intake. Conclusions Elevated serum magnesium levels > 2.10 mEq/L were associated with better survival than low serum magnesium levels